This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

November 6–8, 2023 | Munich, GermanyNovember 14–15, 2023 | Digital Partnering

Ymmunobio AG


Ymmunobio AG is a preclinical stage biotechnology company developing a novel class of immune oncology therapeutic antibodies. The proprietary CEACAM antibodies are having a direct co-stimulatory effect on immune cells in addition to interfering with the CEACAM1 check-point blockade on immune cells. The proprietary antibodies are based on the research of Prof. Bernhard B. Singer, University of Duisburg/Essen in Germany, which has been described in several Nature publications.